United Therapeutics Corporation (UTHR)

234.06 -3.87 (-1.63%) At close: 04:00PM EDT

United Therapeutics Corporation

1000 Spring Street
Silver Spring, MD 20910
United States
301 608 9292
https://www.unither.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 1,168

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D.	Founder, Chairman & CEO	5.32M	56.15M	1955
Mr. Michael I. Benkowitz	President & COO	2.83M	7.83M	1972
Mr. James C. Edgemond	CFO & Treasurer	2.01M	1.49M	1968
Mr. Paul A. Mahon J.D.	Executive VP, General Counsel & Corporate Secretary	2.31M	13.2M	1964
Mr. Dewey Steadman C.F.A.	Head of Investor Relations	N/A	N/A	N/A
Ms. Holly Hobson	Associate Vice President of Human Resources	N/A	N/A	N/A
Kevin T. Gray	Senior Vice President of Strategic Operations & Logistics	N/A	N/A	N/A
Mr. Patrick Poisson	Executive VP of Technical Operations	N/A	N/A	1968
Dr. Leigh Peterson	Executive Vice President of Product Development & Xenotransplantation	N/A	N/A	N/A
Mr. Gil Golden	Senior VP & Chief Medical Officer	N/A	N/A	N/A

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

Corporate Governance

United Therapeutics Corporation’s ISS Governance QualityScore as of April 1, 2024 is 2. The pillar scores are Audit: 1; Board: 5; Shareholder Rights: 3; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.